Cargando…

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features

AIMS: To identify the clinical and histological characteristics of ROS1-rearranged non-small-cell lung carcinomas (NSCLCs) and build a prediction model to prescreen suitable patients for molecular testing. METHODS AND RESULTS: We identified 27 cases of ROS1-rearranged lung adenocarcinomas in 1165 pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jianya, Zhao, Jing, Zheng, Jing, Kong, Mei, Sun, Ke, Wang, Bo, Chen, Xi, Ding, Wei, Zhou, Jianying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/ https://www.ncbi.nlm.nih.gov/pubmed/27648828 http://dx.doi.org/10.1371/journal.pone.0161861

Ejemplares similares

Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
por: Zhao, Jing, et al.
Publicado: (2016)

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015)

Significant Radiologic Response of Pancreatic Metastasis After Targeted Therapy of Ceritinib (LDK378) for ALK-Rearranged Lung Adenocarcinoma Presenting With Hyperglycemia
por: Zheng, Jing, et al.
Publicado: (2017)

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening
por: Zhou, Jianya, et al.
Publicado: (2014)

Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features
por: Cao, Bing, et al.
Publicado: (2015)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Loss of LIMCH1 predicts poor prognosis in patients with surgically resected Lung Adenocarcinoma: A study based on Immunohistochemical Analysis and Bioinformatics
por: Cao, He, et al.
Publicado: (2021)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis
por: Takahara, Yutaka, et al.
Publicado: (2020)

Ipsilateral breast metastasis from lung adenocarcinoma harboring anaplastic lymphoma kinase or ROS1 rearrangement and significant response after targeted therapy: report of two cases
por: Zheng, Jing, et al.
Publicado: (2020)

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Qian, Xiaohan, et al.
Publicado: (2021)

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability
por: Scheffler, Matthias, et al.
Publicado: (2015)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
por: Yue, Dongsheng, et al.
Publicado: (2021)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

The coexistence of ROS1-rearranged lung adenocarcinoma and pulmonary tuberculosis in a critical ill young patient
por: Zhu, Hui, et al.
Publicado: (2019)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)

Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement
por: Shukla, Saumya, et al.
Publicado: (2019)

Mouse Model for ROS1-Rearranged Lung Cancer
por: Arai, Yasuhito, et al.
Publicado: (2013)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta, Anurag, et al.
Publicado: (2020)

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
por: Dong, Liang, et al.
Publicado: (2018)

Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis
por: Wu, Jing-Bo, et al.
Publicado: (2019)

An elderly female patient with ROS1 rearrangement primary lung adenocarcinoma and breast carcinoma: a rare case report and review of the literature
por: Yang, Xiaojuan, et al.
Publicado: (2019)

Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR
por: Shan, Ling, et al.
Publicado: (2015)

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
por: Zhu, You‐cai, et al.
Publicado: (2017)

ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report
por: Taniwaki, Masaya, et al.
Publicado: (2018)

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis
por: Zhang, Shumeng, et al.
Publicado: (2016)

Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements
por: Zou, Yi, et al.
Publicado: (2022)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Overexpression of KIAA0101 Promotes the Progression of Non-small Cell Lung Cancer
por: Cao, He, et al.
Publicado: (2020)

Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients
por: Gao, Qiqi, et al.
Publicado: (2017)

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology
por: Patil, Tejas, et al.
Publicado: (2022)

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
por: Zhou, Jianya, et al.
Publicado: (2018)

Predicting pleural invasion of invasive lung adenocarcinoma in the adjacent pleura by imaging histology
por: Kong, Lingxin, et al.
Publicado: (2023)

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing
por: Cui, Meiying, et al.
Publicado: (2020)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rb9io5d67qt524bmdd0krg8p87